Late-onset biopsy-proven lupus nephritis without other associated autoimmune diseases: severity and long-term outcome
- PMID: 30442061
- DOI: 10.1177/0961203318811603
Late-onset biopsy-proven lupus nephritis without other associated autoimmune diseases: severity and long-term outcome
Abstract
Background/purpose: Lupus nephritis (LN) usually develops within the first years of systemic lupus erythematosus (SLE) onset and rarely after that. There are scarce studies comparing early- versus late-onset nephritis (before versus after five years of SLE diagnosis). The aim of this study was to compare the severity and long-term outcome (after 7 years) in these two, late-onset and early-onset, nephritis groups.
Methods: This study included 93 patients from rheumatology tertiary centers from Brazil and Italy, all of them with biopsy-proven LN with > 7 years follow-up. Patients were divided in two groups: early-onset nephritis ( n = 75) and late-onset nephritis ( n = 18). Clinical and laboratorial data were obtained using a standardized electronic chart database protocol carried out at 1-6 months interval and established in 2000. Patients >50 years or with concomitant autoimmune diseases were excluded. Variables evaluated at the LN presentation were Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), creatinine, albumin, anti-DNA positivity and nephritis class. Variables evaluated at the long-term outcome (after 7 years) were Systemic Lupus International Collaborating Clinics Damage Index (SDI), creatinine, dialysis and mortality.
Results: The average time of LN presentation was 10.94 ± 3.73 years for the late-onset and 1.20 ± 1.60 years for the early-onset group. Their similar nephritis duration (12.44 ± 3.2 versus 13.28 ± 4.03 years, p = 0.41) and comparable mean ages (49.17 ± 9.9 versus 44.11 ± 10.8 years old, p = 0.06) allow a more accurate comparison. Regarding severity, late-onset was similar to early-onset group: SLEDAI (8 (range: 6-22) versus 12 (range: 2-24), p = 0.47), creatinine (1.36 ± 0.94 versus 1.36 ± 1.13 mg/dl, p = 0.99); albumin (2.84 ± 0.65 versus 2.59 ± 0.84 mg/dl, p = 0.30); proteinuria (3.77 ± 2.18 versus 5.01 ± 4.51 g/vol, p = 0.26); proliferative nephritis (44% ( n = 8) versus 60% ( n = 45), p = 0.23). There was also no difference in the long-term outcomes between groups: SDI (1 (range: 0-5) versus 0.5 (range: 0-5), p = 0.27); creatinine (2.04 ± 2.38 versus 1.69 ± 2.26 mg/dl, p = 0.56); dialysis (22% ( n = 4) versus 13% ( n = 10), p = 0.46) and mortality (0% ( n = 0) versus 12% ( n = 9), p = 0.19).
Conclusion: This study provides novel evidence of comparable long-term outcomes between late-onset and early-onset nephritis, which is most likely explained by the observation that at presentation, the clinical, laboratorial and histological features of late-onset and early-onset nephritis are similar. This suggests that there should be no distinct treatment targets and therapeutic interventions for the late- and early-onset groups.
Keywords: Lupus nephritis; early-onset nephritis; late-onset nephritis; outcomes; systemic lupus erythematosus.
Similar articles
-
Worse Renal Presentation and Prognosis in Initial-Onset Lupus Nephritis than Early-Onset Lupus Nephritis.Yonsei Med J. 2020 Nov;61(11):951-957. doi: 10.3349/ymj.2020.61.11.951. Yonsei Med J. 2020. PMID: 33107238 Free PMC article.
-
Long-term renal outcomes and related risk factors of familial systemic lupus erythematosus patients with lupus nephritis .Clin Nephrol. 2018 Oct;90(4):262-269. doi: 10.5414/CN109305. Clin Nephrol. 2018. PMID: 29932408
-
Outcome of lupus nephritis in childhood onset SLE in North and Central India: single-centre experience over 25 years.Lupus. 2016 Apr;25(5):547-57. doi: 10.1177/0961203315619031. Epub 2015 Dec 3. Lupus. 2016. PMID: 26637291
-
Childhood Systemic Lupus Erythematosus: Presentation, management and long-term outcomes in an Australian cohort.Lupus. 2022 Feb;31(2):246-255. doi: 10.1177/09612033211069765. Epub 2022 Jan 16. Lupus. 2022. PMID: 35037500 Review.
-
Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression.Lupus. 2020 Aug;29(9):1011-1020. doi: 10.1177/0961203320932219. Epub 2020 Jun 22. Lupus. 2020. PMID: 32571142 Free PMC article. Review.
Cited by
-
Analysis of clinical and laboratory characteristics and pathology of lupus nephritis-based on 710 renal biopsies in China.Clin Rheumatol. 2020 Nov;39(11):3353-3363. doi: 10.1007/s10067-020-05115-2. Epub 2020 May 20. Clin Rheumatol. 2020. PMID: 32435895
-
Lupus Nephritis: Improving Treatment Options.Drugs. 2022 May;82(7):735-748. doi: 10.1007/s40265-022-01715-1. Epub 2022 Apr 29. Drugs. 2022. PMID: 35486369 Review.
-
Comparison of renal remission and relapse-free rate in initial- and delayed-onset lupus nephritis.Int J Rheum Dis. 2021 Dec;24(12):1500-1509. doi: 10.1111/1756-185X.14228. Epub 2021 Oct 11. Int J Rheum Dis. 2021. PMID: 34636151 Free PMC article.
-
Comparison of complete renal response and mortality in early- and late-onset lupus nephritis: a multicenter retrospective study of a Japanese cohort.Arthritis Res Ther. 2020 Jul 22;22(1):175. doi: 10.1186/s13075-020-02271-3. Arthritis Res Ther. 2020. PMID: 32698892 Free PMC article.
-
Delayed lupus nephritis in the course of systemic lupus erythematosus is associated with a poorer treatment response: a multicentre, retrospective cohort study in Japan.Lupus. 2019 Aug;28(9):1062-1073. doi: 10.1177/0961203319860200. Epub 2019 Jul 11. Lupus. 2019. PMID: 31296139 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources